PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity

Cell Biochemistry and Function

Volumn 32, Issue 4, 2014, Pages 368-377

  Patel, Jessal J ^a,b   Butters, Oliver R ^a   Arnett, Timothy R ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Fenofibrate; Metformin; Osteoblast; Osteoclast; Rosiglitazone; Troglitazone

Indexed keywords

FAT DROPLET; FENOFIBRATE; GLITAZONE DERIVATIVE; METFORMIN; ROSIGLITAZONE; TROGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CHROMAN DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE CELL; BONE STRUCTURE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; HYPERLIPIDEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; RAT; AGONISTS; ANIMAL; BONE DEVELOPMENT; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; METABOLISM; MOUSE; SPRAGUE DAWLEY RAT;

RATTUS;

ADIPOGENESIS; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CHROMANS; FENOFIBRATE; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; LIPID DROPLETS; METFORMIN; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PPAR ALPHA; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES;

EID: 84901788219     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3025     Document Type: Article

References (52)

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2002; 378: 31-40.
2. Pearson-Stuttard J, Bajekal M, Scholes S, et al. Recent UK trends in the unequal burden of coronary heart disease. Heart 2012; 98: 1573-1582.
3. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4-14.
4. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933-944.
5. Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes. Diabetes Care 2008; 31: 845-851.
6. Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168: 820-825.
7. Solomon DH, Cadarette SM, Choudhry NK, et al. A cohort study of thiazolidinediones and fractures in older adults with diabetes. J Clin Endocrinol Metab 2009; 94: 2792-2798.
8. Aubert RE, Herrera V, Chen W, et al. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 2010; 12: 716-721.
9. Cristancho AG, Lazar MA. Forming functional fat: a growing understanding of adipocyte differentiation. Nat Rev Mol Cell Biol 2011; 12: 722-734.
10. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
11. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
12. Lecka-Czernik B. PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep 2010; 8: 84-90.
13. Jackson SM, Demer LL. Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 2000; 471: 119-124.
14. Chan BY, Gartland A, Wilson PJM, et al. PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 2007; 40: 149-159.
15. Marie PJ. Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 2008; 473: 98-105.
16. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 79: 1147-1156.
17. Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARγ2. J Cell Biochem 1999; 74: 357-371.
18. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002; 18: S10-S15.
19. Lecka-Czernik B, Moerman EJ, Grant DF, et al. Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002; 143: 2376-2384.
20. Ali AA, Weinstein RS, Stewart SA, et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005; 146: 1226-1235.
21. Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145: 401-406.
22. Wan Y, Chong LW, Evans RM. PPAR-γ regulates osteoclastogenesis in mice. Nat Med 2007; 13: 1496-1503.
23. Okazaki R, Toriumi M, Fukumoto S, et al. Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999; 140: 5060-5065.
24. Park JY, Bae MA, Cheon HG, et al. A novel PPARγ agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways. Biochem Biophys Res Commun 2009; 378: 645-649.
25. Yang CR, Lai CC. Thiazolidinediones inhibit TNF-α-mediated osteoclast differentiation of RAW264.7 macrophages and mouse bone marrow cells through downregulation of NFATC1. Shock 2010: 33: 662-667.
26. Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 2010; 30: 894-899.
27. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088-2093.
28. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375: 1875-1884.
29. Syversen U, Stunes A, Gustafsson B, et al. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 2009; 9: 10.
30. Meier CR, Schlienger RG, Kraenzlin ME, et al. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000; 283: 3205-3210.
31. Still K, Grabowski P, Mackie I, et al. The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 2008; 83: 285-292.
32. Okamoto H, Iwamoto T, Kotake S, et al. Inhibition of NF-κB signaling by fenofibrate, a peroxisome proliferator-activated receptor-α ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 2005; 23: 323-330.
33. Stumvoll M, Nurjhan N, Perriello G, et al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333: 550-554.
34. Kim YD, Park KG, Lee YS, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008; 57: 306-314.
35. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
36. Molinuevo MS, Schurman L, McCarthy AD, et al. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res 2010; 25: 211-221.
37. Shah M, Kola B, Bataveljic A, et al. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. Bone 2010; 47: 309-319.
38. Bak EJ, Park HG, Kim M, et al. The effect of metformin on alveolar bone in ligature-induced periodontitis in rats: a pilot study. J Periodontol 2009; 81: 412-419.
39. Lee YS, Kim YS, Lee SY, et al. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 2010; 47: 926-937.
40. Sedlinsky C, Molinuevo MS, Cortizo AM, et al. Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats. Eur J Pharmacol 2011; 668: 477-485.
41. Zinman B, Haffner SM, Herman WH, et al. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 134-142.
42. Jeyabalan J, Viollet B, Smitham P, et al. The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int 2013; 24: 2659-2670.
43. Patel JJ, Utting JC, Key ML, et al. Hypothermia inhibits osteoblast differentiation and bone formation but stimulates osteoclastogenesis. Exp Cell Res 2012; 318: 2237-2244.
44. Orriss IR, Taylor SEB, Arnett TR. Rat osteoblast cultures. Methods Mol Biol 2012; 816: 31-41.
45. Orriss IR, Knight GE, Utting JC, et al. Hypoxia stimulates vesicular ATP release from rat osteoblasts. J Cell Physiol 2009; 220: 155-162.
46. Orriss IR, Arnett TR. Rodent osteoclast cultures. Methods Mol Biol 2012; 816: 103-117.
47. Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996; 50: 1087-1094.
48. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-550.
49. Stunes A, Westbroek I, Gustafsson B, et al. The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats. BMC Endocr Disord 2011; 11: 11.
50. Harsløf T, Wamberg L, Møller L, et al. Rosiglitazone decreases bone mass and bone marrow fat. J Clin Endocrinol Metab 2011; 96: 1541-1548.
51. Epstein S, LeRoith D. Diabetes and fragility fractures-a burgeoning epidemic? Bone 2008; 43: 3-6.
52. Trimpou P, Odén A, Simonsson T, et al. High serum total cholesterol is a long-term cause of osteoporotic fracture. Osteoporos Int 2011; 22: 1615-1620.